Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

NASDAQ:VIR - Nasdaq - US92764N1028 - Common Stock - Currency: USD

5.795  +0.18 (+3.3%)

Fundamental Rating

4

VIR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. VIR has a great financial health rating, but its profitability evaluates not so good. VIR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

VIR had negative earnings in the past year.
In the past year VIR has reported a negative cash flow from operations.
In multiple years VIR reported negative net income over the last 5 years.
VIR had negative operating cash flow in 4 of the past 5 years.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

With a Return On Assets value of -37.31%, VIR perfoms like the industry average, outperforming 59.68% of the companies in the same industry.
VIR has a Return On Equity of -45.37%. This is in the better half of the industry: VIR outperforms 67.61% of its industry peers.
Industry RankSector Rank
ROA -37.31%
ROE -45.37%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

VIR's Gross Margin of 98.86% is amongst the best of the industry. VIR outperforms 97.54% of its industry peers.
VIR's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VIR has more shares outstanding
The number of shares outstanding for VIR has been increased compared to 5 years ago.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

VIR has an Altman-Z score of 0.64. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VIR (0.64) is better than 67.08% of its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.64
ROIC/WACCN/A
WACC10.21%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

VIR has a Current Ratio of 8.71. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
VIR has a better Current ratio (8.71) than 75.70% of its industry peers.
A Quick Ratio of 8.71 indicates that VIR has no problem at all paying its short term obligations.
The Quick ratio of VIR (8.71) is better than 75.70% of its industry peers.
Industry RankSector Rank
Current Ratio 8.71
Quick Ratio 8.71
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

VIR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.78%, which is quite good.
The Revenue for VIR has decreased by -13.90% in the past year. This is quite bad
The Revenue has been growing by 55.74% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.63%
Revenue 1Y (TTM)-13.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-26.29%

3.2 Future

VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.43% yearly.
VIR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 61.08% yearly.
EPS Next Y11.1%
EPS Next 2Y9.02%
EPS Next 3Y7.98%
EPS Next 5Y19.43%
Revenue Next Year-60.63%
Revenue Next 2Y-31.93%
Revenue Next 3Y-4.57%
Revenue Next 5Y61.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.02%
EPS Next 3Y7.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (4/22/2025, 2:20:08 PM)

5.795

+0.18 (+3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-01 2025-05-01/amc
Inst Owners61.8%
Inst Owner Change0.08%
Ins Owners2.58%
Ins Owner Change3.18%
Market Cap794.73M
Analysts78.46
Price Target35.26 (508.46%)
Short Float %7.71%
Short Ratio3.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.48%
Min EPS beat(2)-46.72%
Max EPS beat(2)13.76%
EPS beat(4)2
Avg EPS beat(4)2.26%
Min EPS beat(4)-46.72%
Max EPS beat(4)54.8%
EPS beat(8)3
Avg EPS beat(8)-1.87%
EPS beat(12)5
Avg EPS beat(12)-4.05%
EPS beat(16)8
Avg EPS beat(16)194.51%
Revenue beat(2)1
Avg Revenue beat(2)-3.36%
Min Revenue beat(2)-57.23%
Max Revenue beat(2)50.52%
Revenue beat(4)2
Avg Revenue beat(4)77.62%
Min Revenue beat(4)-59.38%
Max Revenue beat(4)376.59%
Revenue beat(8)4
Avg Revenue beat(8)26.46%
Revenue beat(12)6
Avg Revenue beat(12)17.12%
Revenue beat(16)8
Avg Revenue beat(16)13.64%
PT rev (1m)0%
PT rev (3m)17.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.75%
EPS NY rev (1m)9.37%
EPS NY rev (3m)11.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.71
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-3.82
EYN/A
EPS(NY)-3.4
Fwd EYN/A
FCF(TTM)-3.31
FCFYN/A
OCF(TTM)-3.25
OCFYN/A
SpS0.54
BVpS8.39
TBVpS8.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.31%
ROE -45.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.86%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.15%
Cap/Sales 9.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.71
Quick Ratio 8.71
Altman-Z 0.64
F-Score4
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.63%
EPS Next Y11.1%
EPS Next 2Y9.02%
EPS Next 3Y7.98%
EPS Next 5Y19.43%
Revenue 1Y (TTM)-13.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-26.29%
Revenue Next Year-60.63%
Revenue Next 2Y-31.93%
Revenue Next 3Y-4.57%
Revenue Next 5Y61.08%
EBIT growth 1Y19.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.93%
EBIT Next 3Y3.01%
EBIT Next 5Y21.83%
FCF growth 1Y43.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.69%
OCF growth 3YN/A
OCF growth 5YN/A